Mirvetuximab soravtansine-gynx beneficial for FRα-positive ovarian cancer, finds phase 3 trial
For patients with high folate receptor α (FRα)-positive ovarian cancer, a first-in-class antibody-drug conjugate targeting FRα, mirvetuximab soravtansine-gynx (MIRV), shows a significant benefit over chemotherapy, according ...
Dec 7, 2023
0
0